We serve Chemical Name:2-Bromo-4-fluoro-5-(trifluoromethyl)aniline CAS:193090-60-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Bromo-4-fluoro-5-(trifluoromethyl)aniline
CAS.NO:193090-60-7
Synonyms:2-Bromo-4-fluoro-5-(trifluoromethyl)aniline;5-Amino-4-bromo-2-fluorobenzotrifluoride;2-bromo-4-fluoro-5-trifluoromethyl-phenylamine;Benzenamine, 2-bromo-4-fluoro-5-(trifluoromethyl)-;2-Bromo-4-fluoro-5-(trifluoromethyl)benzenamine;MFCD04973755;ZR DF BE EXFFF
Molecular Formula:C7H4BrF4N
Molecular Weight:258.011
HS Code:2921420090
Physical and Chemical Properties:
Melting point:24-29ºC
Boiling point:253.7±40.0 °C at 760 mmHg
Density:1.8±0.1 g/cm3
Index of Refraction:1.504
PSA:26.02000
Exact Mass:256.946320
LogP:3.63
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN2811
Packing Group:III
Contact us for information like 2-Bromo-4-fluoro-5-(trifluoromethyl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ZR DF BE EXFFF physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD04973755 Use and application,2-Bromo-4-fluoro-5-(trifluoromethyl)aniline technical grade,usp/ep/jp grade.
Related News: Some of Amanpour’s counterparts also offered well-wishes on Monday. 2-Bromo-4-fluoro-5-(trifluoromethyl)aniline manufacturer Some of Amanpour’s counterparts also offered well-wishes on Monday. 2-Bromo-4-fluoro-5-(trifluoromethyl)aniline supplier Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. 2-Bromo-4-fluoro-5-(trifluoromethyl)aniline vendor Singapore, Australia, New Zealand, and the United States have banned all foreign nationals traveling from China from entering the country. 2-Bromo-4-fluoro-5-(trifluoromethyl)aniline factory Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.
